文献速递血液净化与透析

特异性乙酰肝素酶抑制逆转葡萄糖诱导的间皮细胞间充质转化

Specific heparanase inhibition reverses glucose-induced mesothelial-to-mesenchymal transition.
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

该体外研究用高糖(200 mM)培养大鼠间皮细胞6天,检测上皮间充质转化标志物和血管内皮生长因子,并观察特异性乙酰肝素酶抑制剂SST0001的作用。结果显示高糖上调VEGF及所有上皮间充质转化标志物的基因和蛋白表达,第3天加入SST0001可逆转这些生物学和细胞效应,并恢复高糖处理期间丢失的正常跨上皮电阻和通透性。作者认为乙酰肝素酶在該过程中起核心作用,药理抑制可能有助于减轻纤维化,但需临床研究或试验确认其临床效用。

要点

  • 高糖(200 mM)培养大鼠间皮细胞6天可诱导上皮间充质转化标志物和VEGF的基因与蛋白显著上调。
  • 第3天加入SST0001可逆转高糖诱导的上述生物学和细胞效应。
  • SST0001抑制乙酰肝素酶还恢复了高糖处理期间丢失的正常跨上皮电阻和通透性。

核心结论

  • 高糖可诱导间皮细胞发生上皮间充质转化,乙酰肝素酶在该过程中起核心作用。
  • 作者认为药理抑制乙酰肝素酶可能成为减轻纤维化、避免腹膜透析患者透析效能快速下降的有价值治疗工具,但需临床研究或试验确认其临床效用。

研究设计与样本

  • 体外研究,采用多种生物分子学策略评估乙酰肝素酶在高糖诱导间皮细胞上皮间充质转化中的作用。
  • 大鼠间皮细胞在高糖(200 mM)培养基中培养6天,加或不加SST0001(一种N-乙酰化糖裂解肝素,具有强抗乙酰肝素酶活性)。
  • 用实时PCR和免疫荧光/蛋白质印迹检测上皮间充质转化标志物(VIM、α-SMA、TGF-β)和血管内皮生长因子。
  • 用Millicell-ERS欧姆计和分光光度计分别测量跨上皮电阻和白蛋白通透性作为功能分析。

主要发现

  • 200 mM葡萄糖培养6天后显著上调VEGF和所有上皮间充质转化标志物的基因和蛋白表达。
  • 第3天加入SST0001可逆转这些生物学和细胞效应。
  • 抑制乙酰肝素酶还恢复了高糖处理期间丢失的正常跨上皮电阻和通透性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需临床研究和/或试验确认该治疗的临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epithelial-to-mesenchymal transition (EMT) of peritoneal mesothelial cells induced by high glucose (HG) levels is a major biological mechanism leading to myofibroblast accumulation in the omentum of patients on peritoneal dialysis (PD). Heparanase (HPSE), an endoglycosidase that cleaves heparan sulfate chains, is involved in the EMT of several cell lines, and may have a major role in this pro-fibrotic process potentially responsible for the failure of dialysis. Its specific inhibition may therefore plausibly minimize this pathological condition. METHODS: An in vitro study employing several biomolecular strategies was conducted to assess the role of HPSE in the HG-induced mesothelial EMT process, and to measure the effects of its specific inhibition by SST0001, a N-acetylated glycol-split heparin with a strong anti-HPSE activity. Rat mesothelial cells were grown for 6 days in HG (200 mM) culture medium with or without SST0001. Then EMT markers (VIM, α-SMA, TGF-β) and vascular endothelial growth factor (VEGF) (a factor involved in neoangiogenesis) were measured by real-time PCR and immunofluorescence/western blotting. As a functional analysis, trans-epithelial resistance (TER) and permeability to albumin were also measured in our in vitro model using a Millicell-ERS ohmmeter and a spectrophotometer, respectively. RESULTS: Our results showed that 200 mM of glucose induced a significant gene and protein up-regulation of VEGF and all EMT markers after 6 days of culture. Intriguingly, adding SST0001 on day 3 reversed these biological and cellular effects. HPSE inhibition also restored the normal TER and permeability lost during the HG treatment. CONCLUSION: Taken together, our data confirm that HG can induce EMT of mesothelial cells, and that HPSE plays a central part in this process. Our findings also suggest that pharmacological HPSE inhibition could prove a valuable therapeutic tool for minimizing fibrosis and avoiding a rapid decline in the efficacy of dialysis in patients on PD, though clinical studies and/or trials would be needed to confirm the clinical utility of this treatment.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Masola V, Granata S, Bellin G, et al. Specific heparanase inhibition reverses glucose-induced mesothelial-to-mesenchymal transition. Nephrol Dial Transplant. 2017. PMID: 28064160. doi:10.1093/ndt/gfw403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。